Business Wire

Global Brands Launch Live RCS Business Messaging Services Based on the GSMA Universal Profile

Del

The GSMA today announced that multiple global brands including 1-800 Contacts, 1-800-Flowers.com, Booking.com, ITV, Snaptravel and Subway have launched live trials of RCS Business Messaging based on the GSMA’s Universal Profile for Advanced Messaging (UP). The service upgrades existing SMS business messaging to create a richer and more interactive experience for consumers, allowing them to engage directly with brands within the messaging platform via artificial intelligence and chatbots. There will be a number of live demonstrations showcased at the GSMA Innovation City at Mobile World Congress in Barcelona.

“In the space of a year, operator RCS launches have almost doubled from 30 to 55, underpinned by the Universal Profile, and have the potential to double again in 2018. Networks are now being interconnected in Europe and the Americas and we are seeing a rapidly growing base of global users,” said Alex Sinclair, Chief Technology Officer, GSMA. “RCS Business Messaging is also being adopted by leading global brands who see the opportunities it presents to engage with consumers in a more interactive and compelling way.”

In the U.S., Google is collaborating with Sprint to enable campaigns with 1-800-Contacts, 1-800-Flowers.com, Booking.com, Express, SnapTravel and Subway in collaboration with messaging partners 3C, CM.com, Mobivity, OpenMarket, Smooch and Twilio launching through Google's Early Access programme. Also in Mexico where they will launch soon, Google is partnering with Telcel to enable campaigns with 5 Piso, Banamex, Broxel, DHL Mexico and Secretaria de Salud in collaboration with messaging partners Airmovil, Auronix, Aldeamo, Movile and Tiaxa. Vodafone, the first mobile operator to commercially launch RCS in 14 countries, is working closely with ITV and OpenMarket to see how RCS can be used to help interact with their viewers. They along with Google are also closely working with IMImobile on Barclays, British Gas, Foxtons and Pizza Hut Delivery. In addition to CLX Communications on Nissan and with Infobip to support Uber in exploring the potential of RCS Business Messaging.

RCS is incorporated natively into a phone’s default messaging service and enables users to enjoy enhanced messaging services such as group chat, video, gifs, file and location sharing, amongst many others, without needing to download an app. RCS Business Messaging takes this further by allowing subscribers to engage directly with multiple brands from one messaging platform to make restaurant reservations, book train tickets or make purchases without having to juggle numerous apps.

Momentum is growing around the world with over 159 million current active monthly RCS users, according to GSMA Intelligence, a figure that is expected to grow to 350 million by Q4 2018. GSMA Intelligence also estimates that the RCS Business Messaging market will be worth over $74 billion by 2021.

The GSMA Universal Profile and Network Interconnection

In a related press release, the GSMA announced that América Móvil, Rogers Communications and Sprint have interconnected their networks across the Americas, while Deutsche Telekom, Telenor Group, Telia Company and Vodafone Group have interconnected in Europe, enabling subscribers in these regions to access advanced RCS across 22 networks in 17 countries. All support the GSMA’s Universal Profile, which is currently backed by over 70 leading operators, vendors and OS providers worldwide and provides an open, consistent and global messaging service across networks and devices. For more information about the Universal Profile, please go to: www.gsma.com/futurenetworks/ip-services/universal-profile/ .

The GSMA Future Networks Programme at MWC 2018

The GSMA Future Networks programme will host a number of seminars on 5G and Messaging as a Platform (MaaP) at MWC 2018. They will also be showcasing a number of interactive demonstrations at the GSMA Innovation City in Hall 4. For further information on all these activities, visit

www.gsma.com/futurenetworks/events-and-webinars/new-mobile-world-congress-2018-barcelona/.

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
Pau Guerrero / Gloria Almirall
+34 93 236 09 00
PGuerrero@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch